Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-8931

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

Merck enlists celebrity chef in Hispanic diabetes campaign

Leticia Moreinos Schwartz will help get healthy eating message to Latin Americans

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

FDA approves Merck’s insomnia drug

Belsomra is first orexin receptor antagonist available in US

- PMLiVE

Merck & Co taps music industry for US HIV campaign

Pharma company to work with music promoter Maria Davis and Positive Women’s Network – USA

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links